- Home
- ZCMD vs GTBP Comparison
ZCMD vs GTBP Comparison
Compare ZCMD & GTBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZCMD | GTBP |
|---|---|---|
| Founded | 2012 | 1965 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.9M | 8.8M |
| IPO Year | 2019 | 2016 |
Fundamental Metrics
Financial Performance| Metric | ZCMD | GTBP |
|---|---|---|
| Price | $0.11 | $0.48 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 7.1M | 2.1M |
| Earning Date | 04-28-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.75 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.08 | $0.26 |
| 52 Week High | $2.29 | $3.73 |
Technical Indicators
Market Signals| Indicator | ZCMD | GTBP |
|---|---|---|
| Relative Strength Index (RSI) | 12.24 | 61.74 |
| Support Level | N/A | $0.39 |
| Resistance Level | $0.71 | $0.79 |
| Average True Range (ATR) | 0.25 | 0.05 |
| MACD | -0.16 | 0.01 |
| Stochastic Oscillator | 1.49 | 98.65 |
Price Performance
Historical ComparisonAbout ZCMD Zhongchao Inc.
ZHONGCHAO Inc is an offshore holding company. Through its subsidiaries, it is a platform-based internet technology company offering services to patients with oncology and other diseases in China. It provides healthcare information, education, and training services to healthcare professionals under its MDMOOC brand. It also provides focused patient management services through the Zhongxun IT system and WeChat mini program, and Zhongxin Health WeChat mini program, to pharmaceutical enterprises and NFP customers.
About GTBP GT Biopharma Inc.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. The company is engaged in discovering, developing, and commercializing therapeutics from its proprietary product platform across various disease areas, mainly focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platform offers immuno-oncology products designed to treat hematologic malignancies, sarcoma, and solid tumors.